Analogue insulin is a sub-group of human insulin. Analogue insulin is laboratory grown but genetically altered to create either a more rapid acting or more uniformly acting form of the insulin.
This can have advantages for blood sugar management
Analogue insulins have been available since just before the start of the new millennium.
HOW IS HUMAN ANALOGUE INSULIN PRODUCED?
Similar to human insulin , analogue insulin is laboratory created by growing insulin proteins within E-coli bacteria (Escherichia coli).
The process goes further through changing the order of amino acids to allow the insulin to be used by the body either more rapidly or more uniformly by the body than with regular human insulin.
This type of process is known as undergoing ‘recombinant DNA’ technology.
WHAT TYPES OF ANALOGUE INSULIN ARE AVAILABLE?
Analogue insulin is available in two main forms, rapid acting and long acting, as well as premixed combinations.
Examples of analogue insulin:
- Rapid acting: Humalog, NovoRapid
- Long acting: Lantus, Levemir, Tresiba
- Premixed analogue insulins: Humalog Mix 25, Humalog Mix 50, NovoMix 30
WHAT ARE PREMIXED ANALOGUE INSULINS?
Premixed analogue insulins combine a ratio of rapid acting and long acting insulin.
For example, Humalog Mix 25 consists of 25% rapid acting and 75% long acting insulin.
HOW QUICKLY DO ANALOGUE INSULINS ACT?
Rapid acting insulins start to act immediately after injecting , with their peak action occurring within the first hour after injecting.
The duration is up to 4 hours.
Long acting insulin takes about 2 hours to start acting, and is designed to act uniformly so that there is no peak activity as such. The duration of long acting insulin is up to 24 hours. Your healthcare team will be able to advise whether you need one or two doses per day.
BENEFITS OF ANALOGUE INSULIN
The primary benefits of analogue insulin are that the rapid acting insulin works as soon as it is injected and long acting insulins have no peak activity.
Rapid acting insulin is particularly useful for people who are insulin dependent as it can help to minimise sharp rises (spikes) in blood sugar shortly after eating.
Long acting analogue insulins have become popular partly because the lack of a peak activity period allows for easier prediction of how it acts and has also gives some people more confidence that they will avoid night time hypos
DISADVANTAGES OF ANALOGUE INSULIN
As with human insulins, it has been reported that analogue insulins may lead to unwanted side effects such as loss of hypo awareness, lethargy and weight gain that might not be found when taking animal insulins.
To date, no conclusive research to confirm or deny this claim is available. Analogue insulins are still a relatively new treatment and therefore there is a lack of long term research. In 2009, a four country study highlighted a potential link between the use of Lantus and the development of cancer
However, after the research was reviewed, the European Medicines Agency found the studies to not be consistent enough to either confirm or deny the link, and therefore cleared Lantus as being safe for use.
PRICE OF ANALOGUE INSULIN
A further disadvantage of analogue insulin is in its price. Analogue insulins cost the NHS over twice as much as non-analogue human insulins.
Follow Tom On:
- Links and Excerpts From PedsCrit: “Intubation Essentials with Dr. Alyssa Stoner and Dr. Gina Patel, Part 4 Sedation & Analgesia Overview JULY 22, 2021 PEDSCRIT
- Links To And Excerpts From “Rate of Workers Enrolled in High-Deductible Health Plans Jumps for 8th Year in Row to Record 55.7%” From ValuePenguin
- “Application of Lung Ultrasound” From MetroHealth Ultrasound
- “POCUS For Pleural Fluid” From MetroHealth Emergency Ultrasound
- Outstanding “Introduction to Lung Ultrasound” from MetroHealth Emergency Ultrasound
- An Outstanding Introduction To ECMO: #79: ECMO Essentials with PedsCrit – It’s All Trains and Potatoes From The Cribsiders
- Links To And Excerpts From “Diagnostic Accuracy of Point-of-Care Ultrasound for Intussusception in Children Presenting to the Emergency Department: A Systematic Review and Meta-analysis”
- Link To PedsCrit‘s “Intubation Essentials with Dr. Alyssa Stoner and Dr. Gina Patel, Part 2 Airway Equipment”
- Link To “PedsCrit’s Intubation Essentials with Dr. Alyssa Stoner and Dr. Gina Patel, Part 1 Preparation and Checklists” With A Link To An Additional Relevant Resource From Emergency Medicine Cases
- Link To “POCUS CHOP PEM Podcast”
- Links To The Complete List Of Pediatric Emergency Medicine Podcasts From The Children’s Hospital Of Philadelphia (CHOP)
- “Emergency Department Clinical Pathway for Healthy Children with Gastroenteritis/ Dehydration” From CHOP
- Link To “December 2022: Which is Best? Manual or Drill for IO Access in Neonates” From Dr. Larry Mellick’s Blog With A Link To An Additional Resource
- Links To And Excerpts From The Cribsiders: “#49: Appendicitis – Tips and Tricks For When It’s the Appendix”
- Links And Excerpts From The Cribsiders: “#33: Febrile Infants – When Babies Are Too Hot”
- Links And Excerpts From The Cribsiders: “#2: Go with the High Flow: Bronchiolitis with Dr. Brian Alverson” With Links To Additional Resources
- Links To And Excerpts From “AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review”
- Outstanding PedsCrit: “PedsCrit Rapid Response Teams with Dr. Nada Mallick and the Cribsiders — Part 2”
- Outstanding PedsCrit: “Rapid Response Teams with Dr. Nada Mallick and the Cribsiders — Part 1”
- Excellent YouTube Video: “Push Dose Pressors for EMS: Epinephrine and Norepinephrine”
- Links And Excerpts: “2023 ESC Guidelines for the management of acute coronary syndromes”
- “Ep 188 Hemoptysis – ED Approach and Management” From Emergency Medicine Cases
- Conjunctivitis From PedsCases With Links To Additional Resources
- “CT for Evaluation of Hemoptysis” From Radiographics
- Links To And Excerpts From “2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee”
- “The Lipid Panel Reimagined: Mind the Gap Segment” From Core IM
- “The Role of Non-Statin Therapies in Optimal Cholesterol Management” From Emory Cardiology Grand Rounds
- “How Did Diabetes Medications Become Weight Loss Meds? Beyond Journal Club on SURMOUNT-1 Trial” From Core IM
- Links To And Excerpts From “CAD-RADS™ 2.0 – 2022 Coronary Artery Disease – Reporting and Data System An Expert Consensus Document . . .”
- Links To Resources On Obesity Medicine